We are really excited to present our work describing over 23,000 liquid biopsy cases to understand the relationship between ctDNA shed and the detection of actionable alterations on plasma testing. Here is a tweetorial describing our work.

👀 Check out what’s popular this week in #JCOPO: Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples 👉 fal.cn/3t8RC Hatim Husain Geoff Oxnard MD #ctDNA #lcsm

Nice study from my FMI colleagues. Improving precision medicine includes identifying futility biomarkers for SOC!

Unique spectrum of BRAF alts in prostate cancer! 👉3% BRAF activated, mostly rearrangements and K601E. 👉Diverse BRAF fusions detected both in tissue DNA (F1CDx) and liquid ctDNA (F1LCDx). Love the teamwork here!🙌 Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Emmanuel Antonarakis Hanna Tukachinsky

Beautiful summary of mCRPC treatment options with recommended algorithms by silke gillessen #GU23

Some next-gen BRAF inhibitors out there already in phase 1/2 trials 🤞Hoping for a future with targeted therapies beyond PARP inhibitors for PC!

Thought-provoking commentary "Alpelisib Efficacy without Cherry-PI3King Mutations" on our paper with Hope Rugo and Geoff Oxnard MD in current CCR issue #breastcancer Foundation Medicine

Bravo Joel W. Neal, MD, PhD , love this paradigm Charu Aggarwal, MD, MPH, FASCO has championed: early LBx 🩸🧬 based on a *clinical diagnosis* of lung cancer, in parallel to pathologic diagnosis🔬!

Appreciate the kind words! A good poster is a health hazard. We talked about liquid biopsies for over 4 hours! Had to be booted🥾out of the poster hall. And the slow walk & ongoing questions shows the VERY HIGH enthusiasm and education needed about #ctDNA. #ASCO23 OncoAlert

Geoff Oxnard MD Vivek Subbiah, MD Relay Therapeutics Brenton Mar I recently heard that ALL the 3 phase-3 trials continue to have very slow accrual🚶‍♀️. 2 have shut down due to slow accrual! Took these companies a long time to realize that you could enroll ctDNA➕. 1/3rd of cholangio; not enough tissue for NGS. 💡🩸 can fill the void.#ASCO23

The level of circulating tumor DNA (ctDNA) shed by a patient’s specific tumor informs the accuracy of blood-based CGP test results. Through a tumor fraction algorithm, our scientists developed a method for quantifying ctDNA in each blood sample: bit.ly/42nOIsy #ASCO23

Thank you Alex Chehrazi-Raffle, MD et al. for collaborating on this important work about BRAF beyond V600E (mutations and fusions): an exciting, potentially targetable biomarker that has been largely overlooked in #prostatecancer.

🎉 My first paper in JLB International Society of Liquid Biopsy! 🤓 A pleasure to collaborate with SCRUM-Japan to describe pan-tumor bTMB 🩸concordance w TMB 🔬& identification of cancer pts w better outcomes on IO: sciencedirect.com/science/articl…

Such an amazing story! The true power of precision medicine and liquid biopsy showcased: oncodaily.com/blog/15969.html

Just published Clinical Cancer Research Is it a myth🐉that you can’t detect fusions on #ctDNA? 👇🏾Presenting one of the largest datasets on #LiquidBiopsies & Fusion🖇️detection 53,842 patients 1️⃣4️⃣% had a pathogenic rearrangement detected Shedding💦matters OncoAlert aacrjournals.org/clincancerres/…

I am glad these results are out. Guidelines jumped the gun on incorporating sidedness for mCRC treatment. Insurance companies started denying therapy even when molecular data pointed otherwise.. Patients suffered. #gi24